Efalizumab: Integrating a new biologic agent into the long-term management of moderate to severe plaque psoriasis Charles Lynde OriginalPaper 20 April 2006 Pages: 1 - 3
Efalizumab, a reversible T-cell modulator for psoriasis Neil H. ShearRichard G. LangleyVincent Ho OriginalPaper 20 April 2006 Pages: 4 - 9
A favourable benefit/risk ratio with efalizumab: A review of the clinical evidence Yves PoulinKim A. PappAditya K. Gupta OriginalPaper 20 April 2006 Pages: 10 - 17
Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches Richard G. LangleyVincent HoCatherine Zip OriginalPaper 20 April 2006 Pages: 18 - 25
Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis Kim A. PappVincent HoCatherine Zip OriginalPaper 20 April 2006 Pages: 26 - 32